Skip Nav Destination
Issues
1 December 2000
ISSN 1078-0432
EISSN 1557-3265
The Biology Behind
Editorials
Editorial
Advances in Brief
Paclitaxel-induced Apoptosis and Mitotic Arrest Assessed by Serial Fine-Needle Aspiration: Implications for Early Prediction of Breast Cancer Response to Neoadjuvant Treatment1
W. Fraser Symmans; Matthew D. Volm; Richard L. Shapiro; A. Bridget Perkins; Alice Y. Kim; Sandra Demaria; Herman T. Yee; Heather McMullen; Ruth Oratz; Paula Klein; Silvia C. Formenti; Franco Muggia
Serum Endostatin Levels Are Elevated and Correlate with Serum Vascular Endothelial Growth Factor Levels in Patients with Stage IV Clear Cell Renal Cancer
Andrew L. Feldman; Lawrence Tamarkin; Giulio F. Paciotti; Byron W. Simpson; W. Marston Linehan; James C. Yang; William E. Fogler; Ewa M. Turner; H. Richard Alexander, Jr.; Steven K. Libutti
Clinical Trials
Phase I Clinical Trial of the Chimeric Monoclonal Antibody (c30.6) in Patients with Metastatic Colorectal Cancer1
Robyn L. Ward; Deborah Packham; Anne M. Smythe; Jayne Murray; Peter Anderson-Stewart; Neil Kitchen; Rosyln Muirhead; Peter Phillips; Peter Gray; Grant Bigg-Wither; Krishnan Prabakaran; Judy Freund; Michael Fullham; Michele Rule; David Dalley; Alan Meagher; Nicholas J. Hawkins; Glenn M. Smith
A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis1
Jeremy P. Braybrooke; Kenneth J. O’Byrne; David J. Propper; Andrew Blann; Mark Saunders; Nicola Dobbs; Cheng Han; Jane Woodhull; Karen Mitchell; Jeremy Crew; Kenneth Smith; Ross Stephens; Trivadi S. Ganesan; Denis C. Talbot; Adrian L. Harris
Clinical Implications of Dihydropyrimidine Dehydrogenase (DPD) Deficiency in Patients with Severe 5-Fluorouracil-associated Toxicity: Identification of New Mutations in the DPD Gene
André B. P. van Kuilenburg; Janet Haasjes; Dick J. Richel; Lida Zoetekouw; Henk Van Lenthe; Ronney A. De Abreu; Jan G. Maring; Peter Vreken; Albert H. van Gennip
Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study1
Charlotte van Kesteren; Esteban Cvitkovic; Adelkrim Taamma; Luis López-Lázaro; Jośe M. Jimeno; Cecilia Guzman; Ron A. A. Mathôt; Jan H. M. Schellens; Jean-Louis Misset; Etienne Brain; Michael J. X. Hillebrand; Hilde Rosing; Jos H. Beijnen
Molecular Oncology, Markers, Clinical Correlates
Nitric Oxide Synthase, Cyclooxygenase 2, and Vascular Endothelial Growth Factor in the Angiogenesis of Non-Small Cell Lung Carcinoma
Aizen J. Marrogi; William D. Travis; Judith A. Welsh; Mohammed A. Khan; Haress Rahim; Henry Tazelaar; Peter Pairolero; Victor Trastek; James Jett; Neil E. Caporaso; Lance A. Liotta; Curtis C. Harris
A Genetic Epidemiological Study of Hereditary Prostate Cancer (HPC) in Finland: Frequent HPCX Linkage in Families with Late-onset Disease1
Johanna Schleutker; Mika Matikainen; Jeffrey Smith; Pasi Koivisto; Agnes Baffoe-Bonnie; Tommi Kainu; Elizabeth Gillanders; Risto Sankila; Eero Pukkala; John Carpten; Dietrich Stephan; Teuvo Tammela; Michael Brownstein; Joan Bailey-Wilson; Jeffrey Trent; Olli-P. Kallioniemi
Experimental Therapeutics, Preclinical Pharmacology
Paclitaxel Enhances the Effects of the Anti-Epidermal Growth Factor Receptor Monoclonal Antibody ImClone C225 in Mice with Metastatic Human Bladder Transitional Cell Carcinoma1
Keiji Inoue; Joel W. Slaton; Paul Perrotte; Darren W. Davis; Christiane J. Bruns; Daniel J. Hicklin; David J. McConkey; Paul Sweeney; Robert Radinsky; Colin P. N. Dinney
Cancer Biology, Immunology, Cytokines
Letter to the Editor
Correspondence re: M. Kondo et al., Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma. Clin. Cancer Res., 5: 4005–4012, 1999.
Tohru Utsunomiya; Mitsuo Shimada; Tatsuya Rikimaru; Keizo Sugimachi; Ken-Ichi Ohkura; Shihoko Kaku; Koji Yamada; Kyushu University; Ken-Ichi Taguchi
Errata
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.